$VANI
Vivani Medical, Inc. Stock $vani

$vani Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000143774918019916 Filed on November 08, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q4
Revenue	$1.767M	$2.246M	$3.109M
YoY Change	-43.17%	39.5%	331.81%
Cost Of Revenue	$1.600M	$1.784M	$1.860M
YoY Change	-13.98%	78.22%	-43.81%
Gross Profit	$167.0K	$462.0K	$1.247M
YoY Change	-86.61%	-24.14%	-148.15%
Gross Profit Margin	9.45%	20.57%	40.11%
Selling, General & Admin	$6.050M	$5.372M	$6.410M
YoY Change	-5.62%	9.57%	12.26%
% of Gross Profit	3622.75%	1162.77%	514.03%
Research & Development	$2.440M	$2.672M	$2.270M
YoY Change	7.49%	46.33%	9.13%
% of Gross Profit	1461.08%	578.35%	182.04%
Depreciation & Amortization	$110.0K	$110.0K	$110.0K
YoY Change	0.0%	-8.33%	-8.33%
% of Gross Profit	65.87%	23.81%	8.82%
Operating Expenses	$8.480M	$9.008M	$8.680M
YoY Change	-2.3%	22.42%	11.42%
Operating Profit	-$8.877M	-$8.546M	-$7.433M
YoY Change	19.43%	26.63%	-28.39%
Interest Expense	$20.00K	$20.00K	$20.00K
YoY Change	0.0%	-33.33%	100.0%
% of Operating Profit
Other Income/Expense, Net			$0.00
YoY Change
Pretax Income	-$8.860M	-$8.520M	-$7.410M
YoY Change	19.57%	26.79%	-28.54%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$8.858M	-$8.522M	-$7.409M
YoY Change	19.56%	26.89%	-28.55%
Net Earnings / Revenue	-501.3%	-379.43%	-238.31%
Basic Earnings Per Share
Diluted Earnings Per Share	-$968.3K	-$990.7K	-$1.041M
COMMON SHARES
Basic Shares Outstanding	72.78M
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.470M	$4.970M	$7.840M
YoY Change	-42.98%	-62.74%	-27.94%
Cash & Equivalents	$4.471M	$4.972M	$7.839M
Short-Term Investments
Other Short-Term Assets	$1.400M	$510.0K	$800.0K
YoY Change	75.0%	10.87%	11.11%
Inventory	$3.250M	$3.604M	$2.700M
Prepaid Expenses
Receivables	$504.0K	$1.194M	$1.831M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$9.620M	$10.28M	$13.17M
YoY Change	-26.93%	-42.0%	-13.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.025M	$1.114M	$1.299M
YoY Change	-21.09%	-16.24%	-12.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$40.00K	$30.00K	$30.00K
YoY Change	33.33%	-25.0%	-25.0%
Other Assets
YoY Change
Total Long-Term Assets	$1.062M	$1.143M	$1.332M
YoY Change	-20.27%	-15.96%	-12.94%
TOTAL ASSETS
Total Short-Term Assets	$9.620M	$10.28M	$13.17M
Total Long-Term Assets	$1.062M	$1.143M	$1.332M
Total Assets	$10.68M	$11.42M	$14.50M
YoY Change	-26.32%	-40.15%	-13.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.305M	$1.546M	$752.0K
YoY Change	73.54%	86.27%	-35.17%
Accrued Expenses	$2.503M	$1.975M	$2.425M
YoY Change	3.22%	-62.16%	-43.87%
Deferred Revenue	$167.0K	$111.0K	$48.00K
YoY Change	247.92%		-43.53%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.598M	$7.528M	$6.615M
YoY Change	14.86%	23.21%	16.87%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.598M	$7.528M	$6.615M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$7.598M	$7.530M	$6.620M
YoY Change	14.77%	23.24%	16.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$269.5M	-$260.6M	-$234.4M
YoY Change	14.97%
Common Stock	$229.0M	$221.8M	$202.2M
YoY Change	13.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.084M	$3.892M	$7.882M
YoY Change
Total Liabilities & Shareholders Equity	$10.68M	$11.42M	$14.50M
YoY Change	-26.32%	-40.15%	-13.76%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q4
OPERATING ACTIVITIES
Net Income	-$8.858M	-$8.522M	-$7.409M
YoY Change	19.56%	26.89%	-28.55%
Depreciation, Depletion And Amortization	$110.0K	$110.0K	$110.0K
YoY Change	0.0%	-8.33%	-8.33%
Cash From Operating Activities	-$7.730M	-$7.460M	-$6.720M
YoY Change	15.03%	59.74%	-4.27%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	-$20.00K	-$90.00K
YoY Change	-77.78%	-33.33%	12.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$20.00K	-$20.00K	-$90.00K
YoY Change	-77.78%	-33.33%	-101.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.240M	4.970M	1.290M
YoY Change	461.24%		760.0%
NET CHANGE
Cash From Operating Activities	-7.730M	-7.460M	-6.720M
Cash From Investing Activities	-20.00K	-20.00K	-90.00K
Cash From Financing Activities	7.240M	4.970M	1.290M
Net Change In Cash	-510.0K	-2.510M	-5.520M
YoY Change	-90.76%	-46.6%	-2308.0%
FREE CASH FLOW
Cash From Operating Activities	-$7.730M	-$7.460M	-$6.720M
Capital Expenditures	-$20.00K	-$20.00K	-$90.00K
Free Cash Flow	-$7.710M	-$7.440M	-$6.630M
YoY Change	16.29%	60.34%	-4.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
CY2018Q3	eyes	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	934000
CY2017Q4	eyes	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	779000
	eyes	Class Of Warrant Or Right Cancelled During Period ClassOfWarrantOrRightCancelledDuringPeriod	676000
	eyes	Class Of Warrant Or Right Cancelled During Period Exercise Price ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice	5
CY2018Q3	eyes	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	14449000
CY2018Q3	eyes	Class Of Warrant Or Right Exercisable Exercise Price ClassOfWarrantOrRightExercisableExercisePrice	2.01
	eyes	Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Life ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualLife	P3Y127D
	eyes	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	5000
	eyes	Class Of Warrant Or Right Exercised During Period Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice	1.47
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001266806
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	72780549
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Small Business EntitySmallBusiness	true
	eyes	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod
	eyes	Class Of Warrant Or Right Issued During Period Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
CY2018Q3	eyes	Class Of Warrant Or Right Outstanding Intrinsic Value ClassOfWarrantOrRightOutstandingIntrinsicValue	5900000
CY2017	eyes	Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife	P3Y328D
	eyes	Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife	P3Y127D
CY2018Q3	eyes	Clinical And Regulatory Expense ClinicalAndRegulatoryExpense	964000
CY2017Q3	eyes	Clinical And Regulatory Expense ClinicalAndRegulatoryExpense	629000
	eyes	Clinical And Regulatory Expense ClinicalAndRegulatoryExpense	3439000
	eyes	Clinical And Regulatory Expense ClinicalAndRegulatoryExpense	1927000
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	SECOND SIGHT MEDICAL PRODUCTS INC
	dei	Trading Symbol TradingSymbol	eyes
	eyes	Common Stock Issuable For Services CommonStockIssuableForServices	109000
	eyes	Common Stock Issuable For Services CommonStockIssuableForServices	195000
CY2018Q3	eyes	Common Stock Value Issuable CommonStockValueIssuable
CY2017Q4	eyes	Common Stock Value Issuable CommonStockValueIssuable	153000
	eyes	Contract With Customer Liability Consideration Received In Advance Of Revenue Recognition ContractWithCustomerLiabilityConsiderationReceivedInAdvanceOfRevenueRecognition	437000
CY2018Q3	eyes	Deposits And Other Assets DepositsAndOtherAssets	29000
CY2017Q4	eyes	Deposits And Other Assets DepositsAndOtherAssets	33000
	eyes	Increase Decrease Accrued Clinical Trial Expenses IncreaseDecreaseAccruedClinicalTrialExpenses	155000
	eyes	Increase Decrease Accrued Clinical Trial Expenses IncreaseDecreaseAccruedClinicalTrialExpenses	-6000
	eyes	Proceeds From Exercise Of Stock Options And Warrants ProceedsFromExerciseOfStockOptionsAndWarrants	417000
	eyes	Proceeds From Exercise Of Stock Options And Warrants ProceedsFromExerciseOfStockOptionsAndWarrants	189000
CY2017Q1	eyes	Repayment Of Notes Receivable For Stock Option Exercises Net RepaymentOfNotesReceivableForStockOptionExercisesNet	1000
CY2017Q3	eyes	Repayment Of Notes Receivable For Stock Option Exercises Net RepaymentOfNotesReceivableForStockOptionExercisesNet	1000
CY2018Q1	eyes	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised	7000
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1546000
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	752000
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1194000
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1831000
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1975000
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2425000
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3152000
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2824000
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-580000
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-572000
CY2018Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	43311000
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	40522000
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	20000
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	981000
CY2017Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	935000
CY2017Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	905000
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1285000
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	627000
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	877000
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	877000
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	905000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2789000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2821000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22268000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21050000
CY2018Q3	us-gaap	Assets Assets	11420000
CY2017Q4	us-gaap	Assets Assets	14497000
CY2018Q3	us-gaap	Assets Current AssetsCurrent	10277000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	13165000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7839000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10875000
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4972000
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13344000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2867000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2469000
CY2017Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.15
CY2018Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.01
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	15130000
CY2018Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14449000
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2017Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70312
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57630
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70312
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57630
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	221774000
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	202156000
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8498000
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6802000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26244000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21071000
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	48000
CY2018Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	111000
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	374000
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1784000
CY2017Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1001000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3287000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3255000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	329000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	345000
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	141000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	11148000
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	24365000
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	18803000
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	12972000
	us-gaap	Inventory Lifo Reserve Effect On Income Net InventoryLIFOReserveEffectOnIncomeNet	-1731000
CY2018Q3	us-gaap	Inventory Net InventoryNet	3604000
CY2017Q4	us-gaap	Inventory Net InventoryNet	2700000
	us-gaap	Interest Income Operating InterestIncomeOperating	69000
CY2018Q3	us-gaap	Inventory Adjustments InventoryAdjustments	2236000
CY2017Q4	us-gaap	Inventory Adjustments InventoryAdjustments	2065000
CY2018Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2707000
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1660000
CY2018Q3	us-gaap	Inventory Gross InventoryGross	5840000
CY2017Q4	us-gaap	Inventory Gross InventoryGross	4765000
	us-gaap	Inventory Lifo Reserve Effect On Income Net InventoryLIFOReserveEffectOnIncomeNet	171000
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	4000
CY2018Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2962000
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2611000
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2332000
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2528000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8208000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8170000
CY2018Q3	us-gaap	Gross Profit GrossProfit	462000
CY2017Q3	us-gaap	Gross Profit GrossProfit	609000
	us-gaap	Gross Profit GrossProfit	1842000
	us-gaap	Gross Profit GrossProfit	1600000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	795000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-299000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-639000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	311000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-447000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	233000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	63000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-25000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-104000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	351000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	668000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1082000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1955000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-291000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-261000
CY2018Q3	us-gaap	Interest Income Operating InterestIncomeOperating	24000
CY2017Q3	us-gaap	Interest Income Operating InterestIncomeOperating	33000
	us-gaap	Interest Income Operating InterestIncomeOperating	67000
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8546000
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6749000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26303000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21176000
CY2017Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	30000
CY2017Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	92000
CY2017Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-86000
CY2018Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	45000
CY2018Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-77000
CY2018Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	24000
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2018Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	771000
CY2017Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	485000
CY2018Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	2362000
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2620000
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11420000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14497000
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7528000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6615000
	us-gaap	Nature Of Operations NatureOfOperations	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div>  Organization and Business Operations</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:18pt;">Second Sight Medical Products, Inc. (“Second Sight,” “we,” “us,” or “the Company”) was incorporated in the State of California in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2003.</div> Second Sight develops, manufactures and markets implantable visual prosthetics to enable blind individuals to achieve greater independence.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:18pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2007,</div> Second Sight formed Second Sight Medical Products (Switzerland) Sàrl, initially to manage clinical trials for its products in Europe, and later to manage sales and marketing in Europe, the Middle East and Asia-Pacific. As the laws of Switzerland require at least <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> corporate stockholders, Second Sight Medical Products (Switzerland) Sàrl is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">99.5%</div> owned directly by us and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.5%</div> owned by an executive of Second Sight as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018. </div>Accordingly, Second Sight Medical Products (Switzerland) Sàrl is considered <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100%</div> owned for financial statement purposes and is consolidated with Second Sight for all periods presented.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:18pt;"> Our current product, the Argus<div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">®</div> II retinal prosthesis system (“Argus II”), entered clinical trials in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2006,</div> received CE Mark approval for marketing and sales in the European Union (“EU”) in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011,</div> and received approval by the United States Food and Drug Administration (“FDA”) for marketing and sales in the United States in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2013.</div> We began selling the Argus II in Europe at the end of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011,</div> Saudi Arabia in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2012,</div> the United States and Canada in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> Turkey in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> Iran, Taiwan, South Korea and Russia in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> and Singapore in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:18pt;">We are currently developing the Orion<div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">®</div> Visual Cortical Prosthesis System (“Orion”), an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms of cancer and trauma. A feasibility study of the Orion device is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles (“UCLA”) and Baylor College of Medicine in Houston (“Baylor”).</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Going Concern</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:18pt;">From inception, our operations have been funded primarily through the sales of our common stock and warrants, as well as from the issuance of convertible debt, research and clinical grants, and limited product revenue generated from the sale of our Argus II product. From <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> we have funded our business primarily through:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:18pt;"> </div> <table border="0" cellpadding="0" cellspacing="0" style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;"> <tr> <td style="vertical-align:top;width:3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:top;width:4%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">●</div> </td> <td style="vertical-align:top;width:93%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Issuance of common stock in our rights offering in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2016, </div>which provided net cash proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$19.5</div> million.</div> </td> </tr> <tr> <td style="vertical-align:top;width:3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:top;width:4%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">●</div> </td> <td style="vertical-align:top;width:93%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Issuance of common stock and warrants in our rights offering in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2017, </div>which provided net cash proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$19.7</div> million.</div> </td> </tr> <tr> <td style="vertical-align:top;width:3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:top;width:4%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">●</div> </td> <td style="vertical-align:top;width:93%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Issuance of common stock through our At Market Issuance Sales Agreement during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fourth</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> which provided <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.1</div> million of net cash proceeds.</div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;"> <tr> <td style="vertical-align:top;width:3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:top;width:4%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">●</div> </td> <td style="vertical-align:top;width:93%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Issuance of common stock in a securities purchase agreement in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2018, </div>which provided net cash proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.0</div> million.</div> </td> </tr> <tr> <td style="vertical-align:top;width:3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:top;width:4%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">●</div> </td> <td style="vertical-align:top;width:93%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Issuance of common stock in a securities purchase agreement in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2018, </div>which provided net cash proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.0</div> million.</div> </td> </tr> <tr> <td style="vertical-align:top;width:3%;"> </td> <td style="vertical-align:top;width:4%;">●</td> <td style="vertical-align:top;width:93%;">Issuance of common stock in a securities purchase agreement in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 2018, </div>which provided net cash proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.0</div> million.</td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;"> <tr> <td style="vertical-align:top;width:3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:top;width:4%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">●</div> </td> <td style="vertical-align:top;width:93%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Revenue of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.1</div> million in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.0</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.0</div> million, for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively, generated by sales of our Argus II product.</div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:18pt;">We entered into stock purchase agreements on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 18, 2018, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 14, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 3, 2018 </div>with entities beneficially owned by Gregg Williams for the purchase of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,467,727,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,225,807</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,756,757</div> shares respectively of common stock priced at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.62,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.55</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.48</div> per share respectively, the last reported sale price of our common stock on each purchase date. Gregg Williams is the Chairman of our Board of Directors. These placements of common stock provided net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.0</div> million, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.0</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.0</div> million respectively.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:18pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> warrants or discounts were provided and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> placement agent or investment banking fees were incurred in connection with these transactions. The shares issuable to the purchasers under the Securities Purchase Agreements were also issued pursuant to the exemption from registration under Rule <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">506</div> of Regulation D. We relied on this exemption from registration based in part on representations made by the purchasers.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:18pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2017, </div>we entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley FBR Inc. and H.C. Wainwright & Co., LLC, as agents (“Agents”) pursuant to which we <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>offer and sell, from time to time through either of the Agents, shares of our common stock having an aggregate offering price as set forth in the Sales Agreement and a related prospectus supplement filed with the SEC. We agreed to pay the Agents a cash commission of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.0%</div> of the aggregate gross proceeds from each sale of shares under the Sales Agreement. During <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2018, </div>we sold <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.2</div> million shares of common stock which provided net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.0</div> million under the Sales Agreement. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> shares have been sold since <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2018 </div>under the Sales Agreement.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:18pt;">Our financial statements have been presented on the basis that our business is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We are subject to the risks and uncertainties associated with a business with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> product line and limited commercial product revenues, including limitations on our operating capital resources and uncertain demand for our products. We have incurred recurring operating losses and negative operating cash flows since inception, and we expect to continue to incur operating losses and negative operating cash flows for the foreseeable future. Management has concluded that there is substantial doubt about our ability to continue as a going concern, and our independent registered public accounting firm, in its report on our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> consolidated financial statements, has raised substantial doubt about our ability to continue as a going concern.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:18pt;">We do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have sufficient funds to support our operations for the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months from the date of issuance of these financial statements. We anticipate that we will seek to fund our operations through public or private equity or debt financings, grants, collaborations, strategic partnerships or other sources. However, we <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be unable to raise additional capital or enter into such other arrangements when needed on favorable terms or at all. If we are unable to obtain funding on a timely basis, we <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be required to significantly curtail, delay or discontinue <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more of our research or development programs or the commercialization Argus II or any other approved product candidates, or we <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be unable to expand our operations, maintain our current organization and employee base or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:18pt;"> </div></div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19356000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19879000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-144000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-181000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22079000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17233000
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-7548000
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-6843000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-6716000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-9753000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-7961000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-8522000
	us-gaap	Net Income Loss NetIncomeLoss	-26236000
	us-gaap	Net Income Loss NetIncomeLoss	-21107000
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	9008000
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	7358000
	us-gaap	Operating Expenses OperatingExpenses	28145000
	us-gaap	Operating Expenses OperatingExpenses	22776000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-8000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	36000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	144000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	181000
CY2018Q3	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2017Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	507000
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	795000
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	2000
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	19688000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18939000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4266000
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4123000
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1114000
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1299000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-6000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-128000
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2672000
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1826000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7567000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5622000
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-260613000
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-234377000
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2246000
CY2017Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1610000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5129000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4855000
CY2018Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3040000
CY2017Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2375000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8931000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7057000
	us-gaap	Share Based Compensation ShareBasedCompensation	2789000
	us-gaap	Share Based Compensation ShareBasedCompensation	2821000
	us-gaap	Stock Issued1 StockIssued1
	us-gaap	Stock Issued1 StockIssued1	20000
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	132996
CY2017Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	189000
CY2018Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	261000
CY2017Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	65000
CY2017Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	65000
CY2017Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	65000
CY2018Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	65000
CY2018Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	44000
CY2017Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	19668000
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3992000
CY2018Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9978000
CY2018Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4969000
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	7882000
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	3531000
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	6544000
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	3892000
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68763000
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	56799000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	64113000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53206000

Files In Submission

Name	View Source	Status
0001437749-18-019916-index-headers.html	Edgar Link	pending
0001437749-18-019916-index.html	Edgar Link	pending
0001437749-18-019916.txt	Edgar Link	pending
0001437749-18-019916-xbrl.zip	Edgar Link	pending
ex_127060.htm	Edgar Link	pending
ex_127061.htm	Edgar Link	pending
ex_127062.htm	Edgar Link	pending
eyes-20180930.xml	Edgar Link	completed
eyes-20180930.xsd	Edgar Link	pending
eyes-20180930_cal.xml	Edgar Link	unprocessable
eyes-20180930_def.xml	Edgar Link	unprocessable
eyes-20180930_lab.xml	Edgar Link	unprocessable
eyes-20180930_pre.xml	Edgar Link	unprocessable
eyes20180930_10q.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VANI
Vivani Medical, Inc. Stock $vani

2018 Q4 Form 10-Q Financial Statement

#000143774918019916 Filed on November 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VANI Vivani Medical, Inc. Stock $vani

2018 Q4 Form 10-Q Financial Statement

#000143774918019916 Filed on November 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VANI
Vivani Medical, Inc. Stock $vani